Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis

Inclusion Criteria: * Male and female subjects ≥18 years of age. Where relevant, parents will also sign the informed consent according to local laws and regulations * Patients with diagnosis of chronic non-infectious intermediate uveitis, posterior uveitis or panuveitis in at least one eye * Evidence of active intermediate, posterior or panuveitis (grade ≥ 2+ vitreous haze with or without the presence of anterior chamber cells) at screening and baseline in at least one eye * Requirement for any of the following immunosuppressive therapies for the treatment or prevention of uveitis: * Prednisone or equivalent ≥10 mg daily at any time within the past 3 months. * ≥1 periocular injection or ≥1 intravitreal corticosteroid injection (e.g. triamcinolone) in the study eye within the past 6 months (the last injection must not have been given 6 weeks prior to screening). * Treatment with either cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil, mycophenolic acid, methotrexate at any time within the past 3 months (Patients treated with chlorambucil or cyclophosphamide within the past 5 years are ineligible for the study). * Patients not meeting the above specified criteria for immunosuppressive therapies are eligible for enrollment if they are intolerant to systemic immunosuppressive therapy as determined by the study investigator. * Patient must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written…